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Podocyte injury associated glomerulopathies induced by
pamidronate.
Background. Pamidronate has been demonstrated to de-
crease bone-related complications in multiple myeloma and
delay progression of the disease. This has led to its use in sup-
portive and maintenance therapy of myeloma in conjunction
with steroids and chemotherapy. It has also been selectively
used in patients with breast cancer and other neoplasms.
Methods. We report on five patients who developed glomeru-
lar disease induced by pamidronate. Pamidronate was the only
drug common to all patients. Tests for hepatitis B and C and
human immunodeficiency virus (HIV) were negative for all pa-
tients. The first two patients received a high dose of pamidronate
for 8 weeks, whereas the other three patients were on monthly
therapy for a prolonged period of time. Sources of data included
chart review and pathologic analysis of kidney biopsy.
Results. Three patients were female and two were males
and all were Caucasian, ranging in age from 58 to 71 years.
Renal biopsy findings included minimal change disease in two,
focal segmental glomerulosclerosis in two, and collapsing focal
segmental glomerulosclerosis in one. Immunofluorescence was
essentially negative in all cases. Electron microscopy showed
variable podocyte injury and extensive foot process effacement.
There was no evidence of multiple myeloma-related renal dis-
ease. After the biopsy, pamidronate was discontinued and renal
function stabilized in all patients except the one with the collaps-
ing variant of focal segmental glomerulosclerosis who required
hemodialysis. Three patients had resolution of proteinuria, one
patient continued to have proteinuria without deterioration in
renal function.
Conclusion. Pamidronate has been mainly associated with
collapsing focal segmental glomerulosclerosis. This report ex-
pands that relationship and adds other glomerular diseases
linked with podocyte injury. Additional studies are needed to
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define the cause of the variability of renal histology with this
agent.
Pamidronate (Aredia) is a second-generation bispho-
sphonate that inhibits bone resorption by direct and in-
direct actions on osteoclasts. In addition, pamidronate
inhibits production of cytokines such as interleukin-6
(IL-6) by bone marrow stromal cells [1] and may alter
tumor cell adhesion to stroma [2] critical for the survival
of the myeloma clone. At the University of Arkansas
for Medical Sciences, pamidronate has been incorpo-
rated into the standard protocol for treatment of pa-
tients with multiple myeloma with most patients receiving
pamidronate once a month while a small number of pa-
tients were treated as part of a regimen using high-dose
pamidronate. Pamidronate has also seen increased use in
patients with other types of neoplasms, including breast
cancer.
Side-effects of pamidronate have been relatively in-
frequent. However, recent reports have demonstrated
an association between the use of pamidronate and the
development of the collapsing variant of focal segmen-
tal glomerulosclerosis [3, 4]. These patients developed
proteinuria and progressive renal insufficiency due to
collapsing focal segmental glomerulosclerosis on renal
biopsy. Herein, we report on five patients who received
pamidronate for the treatment of multiple myeloma or
breast cancer and subsequently developed proteinuria
and underwent renal biopsy. Only one patient had col-
lapsing focal segmental glomerulosclerosis, while the oth-
ers had minimal change disease or the classic form of focal
segmental glomerulosclerosis.
METHODS
Renal biopsy specimens were handled as in our previ-
ous studies [5, 6]. Briefly, tissues for light microscopy were
fixed in formalin, dehydrated, embedded in paraffin and
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Table 1. Clinical characteristics of patients with pamidronate-induced nephrotic syndrome
Patient
1 2 3 4 5
Age years 71 58 70 62 70
Gender Female Female Male Male Female
Neoplasm Multiple myeloma Multiple myeloma Multiple myeloma Multiple myeloma Breast cancer
Pamidronate
Induction 50 mg/day × 7 days every 50 mg/day × 7 days every 90 mg 90 mg 90 mg
other week × 2 months other week × 2 months
Maintenance 50 mg/month 50 mg/month 90 mg/3 weeks 90 mg/month 90 mg/month
Total 1450 mg 1500 mg 3960 mg 3780 mg 1170 mg
Duration 4 months 5 months 33 months 41 months 12 months
cut at 3 microns. Serial sections were stained with hema-
toxylin and eosin, periodic-acid Schiff (PAS) reagent,
trichrome, or Jones silver. Tissues for immunofluores-
cence were transported in Michel’s transport media,
washed, snap frozen, and 5 micron cryostat sections
stained for IgG, IgM, IgA, C3, C1q, fibrinogen, and kappa
and lambda light chains. Sections were examined us-
ing an Olympus BX51 microscope (Melville, NY, USA)
equipped with epifluorescence and an Optronics Digi-
tal Photography System (Goleta, CA, USA) in conjunc-
tion with a G4 Macintosh computer (Cupertino, CA,
USA). For electron microscopy, specimens were fixed in
glutaraldehyde, dehydrated, embedded in epon-araldite,
thin sectioned and examined in a Jeol 1010 electron mi-
croscope (Peabody, MA, USA).
RESULTS
The patient characteristics were typical for the un-
derlying diseases necessitating the use of pamidronate
(Table 1). There were three women and two men with an
average age of 66 years (range 58 to 71 years). Multiple
myeloma was the underlying neoplasm in four patients
and breast cancer in one. The patient with breast cancer
was 20 years postprimary excision and treatment when
bony metastases were discovered. Human immunodefi-
ciency (HIV) testing was negative in all patients. Three of
the four patients with multiple myeloma were also receiv-
ing thalidomide at the onset of proteinuria. Pamidronate
administration is detailed in Table 1. Briefly, patients 1
and 2 received 50 mg/day for 7 days every other week
for 2 months, then 50 mg once a month as maintenance.
Patient 3 received 90 mg once every 3 weeks and patients
4 and 5 received 90 mg monthly.
Renal biopsy results varied from minimal change dis-
ease through focal segmental glomerulosclerosis to the
collapsing variant of focal segmental glomerulosclerosis
(Figs. 1 to 3) (Tables 2 and 3). Immunofluorescence was
essentially negative in all but the biopsy from the first pa-
tient in which generalized and diffuse mesangial deposits
of IgM and C3 were seen. The pathologic criteria for so-
called IgM nephropathy remain unclear. In the absence
of ultrastructural evidence of mesangial electron dense
deposits, this case was called minimal change disease.
Fig. 1. Renal biopsy from patient 3. (A) One unremarkable glomeru-
lus with no evidence of segmental sclerosis or hypercellularity. The
loops adjacent to the exit point of the proximal tubule (∗) are not
collapsed [periodic-acid Schiff (PAS) ×400]. (B) Electron photomi-
crograph showing extensive foot process effacement (arrow) and no
deposits (×18000).
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Fig. 2. Renal biopsy from patient 2. One glomerulus with two areas
of segmental loop collapse and sclerosis (single and double arrows)
[periodic-acid Schiff (PAS) ×400].
Electron microscopy demonstrated extensive effacement
of foot processes in all cases. No electron-dense deposits
were evident and no other ultrastructural abnormalities
were noted. Monoclonal immunoglobulin deposition dis-
ease, cast nephropathy and amyloidosis were not found.
Pamidronate was discontinued and various treatments
were instituted (Table 2). Pamidronate was infused, as
per local pharmacy protocol, at a dose of 90 to 180 mg
in 1000 mL of normal saline at a rate of 1 to 1.5 mg/min.
Most of the patients received 90 mg over 2 hours.
Case 1
A 71-year-old white female was found to have IgA-
lambda multiple myeloma in 1995. She had no evidence of
renal involvement and, in 1998, a 24-hour urine collection
contained only 144 mg of protein. Urine electrophore-
sis was negative for monoclonal light chain proteins.
Serum creatinine was stable between 1.1 to 1.3 mg/dL
through 1999. She received pamidronate and thalidomide
starting in July 1999. The protocol included high-dose
pamidronate (50 mg continuous intravenous infusion
daily for a week on alternate weeks for a total of 4 weeks
of infusion and 50 mg intravenously once a month as
maintenance). In October 1999 her multiple myeloma
was in remission following chemotherapy. She com-
plained of generalized fatigue and malaise and mild ankle
swelling. A routine urinalysis showed 3+ protein and a
24-hour urine study showed 10 g of protein without ev-
idence of light chains. Urine sediment was negative for
red blood cells or red blood cell casts. Blood urea nitro-
gen was 16 mg/dL and serum creatinine was 1.2 mg/dL.
Past history was significant for 10 years of hypertension
treated with nifedipine and dyazide. She denied alcohol
Fig. 3. Renal biopsy from patient 5. (A) One glomerulus with exten-
sive loop collapse and prominent epithelial cell proliferation features
[periodic-acid Schiff (PAS) ×400]. (B) A second glomerulus with col-
lapsing features and epithelial cell activity (Jones Silver ×400).
or nonsteroidal anti-inflammatory drugs use and family
history was negative for renal disease. Blood pressure was
110/60 and physical examination was remarkable only for
mild lower extremity edema.
Renal ultrasound revealed normal size kidneys without
evidence of hydronephrosis and a renal biopsy was per-
formed. There were four glomeruli available for light mi-
croscopy without cellular proliferation, mesangial matrix
expansion, or segmental sclerosis. There was mild focal
interstitial inflammation at areas of mild interstitial fibro-
sis. Immunofluorescence was positive for mesangial IgM
and C3 but was otherwise negative. Ultrastructural ex-
amination revealed almost complete effacement of foot
processes but no segmental sclerosis or electron dense
deposits were observed. Mild podocyte swelling and
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Table 2. Renal biopsy in patients with pamidronate-induced nephrotic syndrome
Patient
1 2 3 4 5
Renal biopsy
Light microscopy MCNS FSGS FGS and MCNS FSGS Collapsing FSGS
Proteinuria
Baseline 144 mg/24 hours 338 mg/24 hours 140 mg/24 hours 150 mg/24 hours ND
At biopsy 10 g/24 hours 10 g/24 hours 3.7 g/24 hours 2.3 g/24 hours 14.7 g/24 hours
Latest 388 mg/24 hours 12.5 g/24 hours 136 mg/dL 150 mg/24 hours NA
Creatinine at biopsy 1.2 mg/dL 1.1 mg/dL 2.8 mg/dL 1.3 mg/dL 2.3 mg/dL
Latest creatinine 1.1 mg/dL 1.1 mg/dL 2.0 mg/dL 2.0 mg/dL Hemodialysis
Treatment Steroids, ACE inhibitors ACE inhibitors ACE inhibitors ACE inhibitors ACE inhibitors, CSA
Duration of follow-up 3 years 1 year 2 years 2 years 1 year
Outcome Proteinuria improved No change in Proteinuria and Proteinuria improved ESRD
and creatinine stable proteinuria serum creatinine and rise in creatinine
or creatinine improved
Abbreviations are: MCNS, minimal change nephrotic syndrome; FSGS, focal segmental glomerulosclerosis; ACE, angiotensin-converting enzyme; CSA = cyclosporine
A; ND, not done; NA, not applicable; ESRD, end stage renal disease.
Table 3. Renal biopsy summary
Light microscopy Electron microscopy
Total TI Immunofluorescence Foot process Microvillous
Case glomeruli GS FSGS changes microscopy effacement change Deposits Diagnosis
1 4 0 0 1+ 3+ IgM and C3 mesangium 3+ 2+ Negative MCNS
2 7 2 1 1+ Negative 3+ 3+ Negative FSGS
3 40 18 0 2+ Negative NA NA N/A MCNS and FGS
4 15 9 1 3+ Negative 2+ 2+ Negative FSGS
5 12 4 6 (collapsing) 2+ Negative 3+ 2+ Negative cFSGS
Abbreviations are: NA, not available; GS, global sclerosis; TI, tubulointerstitial; MCNS, minimal change nephrotic syndrome; FSGS, focal segmental glomeruloscle-
rosis; FGS, focal global sclerosis; cFSGS, collapsing focal segmental glomerulosclerosis.
Immunofluorescence stains included IgG, IgM, IgA, C3, C4, fibrinogen, kappa and lambda light chains 1+ = 10% to 15%; 2+ = 15% to 50%; 3+ = >50%.
moderate microvillous changes were seen. A diagnosis
of minimal change disease was made.
The patient was a given steroids for total of 12 weeks
but the proteinuria remained unchanged. The patient was
started on lisinopril and her proteinuria gradually im-
proved. During the latest follow up, 3 years after the onset
of nephrotic range proteinuria, a 24-hour urine collection
showed only 388 mg of proteinuria. Serum creatinine has
remained stable.
Case 2
A 58-year-old white female developed bilateral lower
extremity weakness in early 1999 and spinal cord com-
pression at the level of T12 secondary to a plasmacy-
toma was discovered. On further evaluation, the patient
was found to have an IgG-kappa light chain multiple
myeloma. In August 1999, she received pamidronate/
thalidomide using the same protocol as patient 1. She had
a 24-hour urine collection prior to therapy that showed
338 mg proteinuria/day. Proteinuria was found on routine
follow up in November 1999 and she was found to have
10 g proteinuria/day without light chains. Serum creati-
nine remained at baseline, 1.1 mg/dL, and serum albumin
was 3.5 mg/dL. Renal biopsy contained seven glomeruli,
two of which were globally sclerotic. One glomerulus
had segmental loop collapse near the vascular pole with
an adhesion to Bowman’s capsule and focal hyaline and
lipid material around the sclerosed loops. The tubuloin-
terstitial area showed mild tubular atrophy and intersti-
tial fibrosis. Focal intimal fibrosis was seen in one larger
artery. All immunofluorescence stains were essentially
negative. Electron microscopy demonstrated extensive
foot process effacement but no electron-dense deposits or
hypercellularity. There was mild podocyte swelling and
extensive microvillous proliferation. A diagnosis of focal
segmental glomerulosclerosis (without “collapsing” fea-
tures) was made.
Pamidronate was discontinued and the patient was ini-
tiated on a small dose of an angiotensin II-converting
enzyme (ACE) inhibitor. However, proteinuria contin-
ued and 1 year later remained high at 12.5 g/24 hours.
She was subsequently lost to follow up.
Case 3
A 70-year-old white male had stage IIIB multiple
myeloma diagnosed in 1994 and was initially treated
with a combination of melphalan and prednisone from
June 1994 to February 1996. Subsequently, he received
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high-dose melphalan therapy and underwent peripheral
blood stem cell transplant in August and again in Novem-
ber 1996 that resulted in a partial remission. He re-
lapsed in March 1997 and was treated with a combination
of cytoxan, dexamethasone, etoposide, and cis-platinum
(CDEP). During and after chemotherapy, serum creati-
nine remained stable at 1.3 mg/dL. In September 1997,
he was begun on pamidronate 90 mg once every 3 weeks.
This was continued from September 1997 until May 2000,
when he was found to have nephrotic range proteinuria
(3.7 g/24 hours). Also, the serum creatinine had slowly in-
creased (1.3 mg/dL in 1998, 1.4 mg/dL in February 1999,
1.7 mg/dL in July 1999, and 2.8 mg/dL in April 2000).
He was not receiving any other medication. The patient
denied the use of nonsteroidal anti-inflammatory drugs.
Physical examination was unremarkable.
A renal biopsy was performed and showed 40
glomeruli, 18 of which were globally sclerotic. There was
no segmental sclerosis, hypercellularity, or evidence of
membranous nephropathy. There was moderate tubular
atrophy with interstitial fibrosis. Blood vessels showed
patchy, moderate intimal fibrosis. Immunofluorescence
stains were negative. Electron microscopy was not done
per the order of the requesting physician. Focal global
sclerosis and minimal change disease were the final
diagnoses.
Pamidronate was discontinued and he was started on
lisinopril. At the most recent evaluation 2 years later, his
proteinuria had decreased to 136 mg/24 hours and serum
creatinine had improved to 2.0 mg/dL.
Case 4
A 62-year-old white male was found to have multi-
ple myeloma in 1996 following a myeloma-induced com-
pression fracture of the spine. He received three courses
of vincristine, adriamycin, dexamethasone (VAD) be-
tween November 1996 and January 1997 and a course
of cytoxan in March 1997 followed by high-dose melpha-
lan and peripheral blood stem cell transplants in May
and September 1997. He achieved a complete remis-
sion and was placed on dexamethasone and pamidronate,
90 mg/month, from October 1997 until March 2001. In
January 2001, he was found to have proteinuria 2 g per
24 hours. At that time, he was also receiving thalidomide
100 mg daily at night.
In March 2001, 24-hour urinary protein excretion was
1.18 g with a serum creatinine of 1.3 mg/dL and a cre-
atinine clearance of 69 mL/min. A subsequent 24-hour
urine protein was 2.29 g/24 hours.
Renal biopsy revealed global sclerosis in nine of 15
glomeruli. One glomerulus had an area of segmental loop
collapse and sclerosis without collapsing features. Moder-
ate to severe tubular atrophy and interstitial fibrosis was
seen. Immunfluorescence stains were negative. Electron
microscopy had one glomerulus with an area of segmental
sclerosis but no collapsing features. Moderate foot pro-
cess effacement and microvillous change was present but
no electron dense deposits were seen. The final diagnoses
were focal segmental glomerulosclerosis.
The patient was treated with lisinopril. Proteinuria de-
creased significantly to 150 mg/24 hours during the latest
follow-up 2 years after the initial event. However, during
that visit, serum creatinine increased to 2.0 mg/dL and
lisinopril was switched to tenormin.
Case 5
A 70-year-old white female had surgically treated
breast cancer in 1980. Bony metastases were discovered
in her skull and long bones in 1995 were treated with
hormonal therapy. She received 13 doses of pamidronate
90 mg intravenously monthly beginning in June 2000,
and continuing through May 2001. Serum creatinine was
1.3 mg/dL in October 2000, 1.9 mg/dL in December 2000,
and 2.3 mg/dL in February 2001. Urinary protein was
found to be 14.7 g/g creatinine in February 2001. Serum
protein electrophoresis revealed only hypoalbuminemia.
Antinuclear antibody, hepatitis C antibody, HIV anti-
body, and hepatitis B surface antigen were negative.
A kidney biopsy was performed and 12 glomeruli were
available for light microscopy, four of which were glob-
ally sclerotic. Six glomeruli showed extensive, implosive
loop collapse with epithelial cell swelling and prolifer-
ation overlying the collapsing areas. Numerous protein
droplets were present in and around the collapsed ar-
eas. There was moderate tubular atrophy and intersti-
tial fibrosis. Immunofluorescence stains were negative.
Extensive, almost complete, foot processes effacement
was observed. Prominent podocyte enlargement and mi-
crovillous change was seen. Many loops were collapsed.
No electron-dense deposits were present. The final diag-
nosis was focal segmental glomerulosclerosis, collapsing
variant.
She was treated with prednisone and cyclosporine and
ACE inhibitor, but progressed to end-stage renal failure
over the next 3 months. At last follow-up, 1 year after
renal biopsy, she remains on dialysis.
DISCUSSION
The association of pamidronate and the collapsing vari-
ant of focal segmental glomerulosclerosis have been de-
scribed [3, 7]. In their report, the first to document the
relationship between pamidronate and collapsing focal
segmental glomerulosclerosis, Markowitz et al [3] out-
lined the experimental data suggesting that high-dose
pamidronate can cause both tubular and podocyte epithe-
lial cell toxicity. Their patient population differed from
patients with the idiopathic form of collapsing focal seg-
mental glomerulosclerosis and all had received high-dose
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pamidronate that was temporally associated with the de-
velopment of biopsy-proven collapsing focal segmental
glomerulosclerosis.
Our study developed from an original group of
three patients with multiple myeloma who developed
nephrotic syndrome while on thalidomide therapy. As
we searched for a link between nephrotic syndrome and
thalidomide, we had two more patients who developed
nephrotic syndrome unrelated to multiple myeloma and
not on the thalidomide protocol. The last patient had
breast carcinoma and was not receiving thalidomide.
Pamidronate was the only drug common to all six pa-
tients. Additionally, thalidomide has not been reported
to cause proteinuria or renal toxicity in animal or human
studies.
Pamidronate is a second-generation bisphosphonate
that is frequently used to treat hypercalcemia and has
been demonstrated to decrease bone related compli-
cations in multiple myeloma and delay progression of
myeloma. This has led to its use in supportive and mainte-
nance therapy of patients with multiple myeloma in con-
junction with steroids and chemotherapy. In addition, it
was selectively used in patients with breast cancer. Tran-
sient proteinuria and decreased creatinine clearance have
been observed following intravenous infusion of large
doses of bisphosphonates, including etidronate [8], clo-
dronate [9], and tiludronate [10]. A transient rise in the
level of malate dehydrogenase has been reported in an-
imal studies after a single-dose infusion of pamidronate
[11]. This enzyme is the most sensitive and reliable marker
of renal injury prior to histologic changes [12]. At higher
doses (5 to 50 mg/kg), pamidronate causes elevation of
blood urea nitrogen (BUN) and reduction of creatinine
clearance in rats [13]. In animal studies, pamidronate
in a dose of >10 mg/kg was associated with increased
urinary excretion of gamma glutamyl transpeptidase, in-
dicating loss of renal tubular brush border [14]. Renal
biopsy of these mice revealed focal cellular necrosis,
increased number of vesicles, and/or dilated vacuoles
and loss of brush border [14]. It has also been shown
that once proximal tubular damage occurs, active se-
cretion of pamidronate is impaired, thus prolonging the
half-life of pamidronate [14]. Hence, it is possible that
more frequent pamidronate infusion may be associated
with higher incidence of proteinuria and focal segmental
glomerulosclerosis.
Two of our patients received daily infusions of
pamidronate. Although 50 mg continuous infusion over
1 day is a relatively low dose, the half-life of pamidronate
is 28 hours. Therefore, daily infusion would result in
much higher concentration of pamidronate in the serum
than the usual dose of once every 3 to 4 weeks. Thus,
this specific pamidronate protocol for multiple myeloma
may have increased the risk for proteinuria. However, six
other patients on this pamidronate schedule did not de-
velop proteinuria. This suggests that there is individual
variability in the renal response to pamidronate.
In contrast to the previous reports of Markowitz et al
[3, 7], only one patient developed collapsing focal
segmental glomerulosclerosis. Lockridge, Papac, and
Perazella [15] reported another variant of pamidronate
renal toxicity in a patient with Langerhan’s histiocyto-
sis treated with monthly pamidronate. This patient pre-
sented with nephrotic syndrome and acute renal failure
that had developed over 2 weeks. Renal biopsy showed
severe acute tubular injury and minimal change dis-
ease. In another study of myeloma patients receiving
pamidronate, Desikan et al [4] reported focal segmental
glomerulosclerosis in two patients. The common theme
in all these cases is podocyte injury [16]. Podocytes form
the final barrier to protein loss, which explains why
podocyte injury is typically associated with marked pro-
teinuria [17]. Podocytes are injured in many forms of
human and experimental glomerular diseases, includ-
ing minimal change disease, focal segmental glomeru-
losclerosis, and membranous glomerulous nephropathy,
among others [18]. In addition, podocytes are target for
many forms of injury, including antibodies to podocyte
membrane, hemodynamic injury, gene mutation, toxins,
infections such as HIV, and idiopathic such as focal seg-
mental glomerulosclerosis [19, 20]. This makes podocyte
injury the most likely target for pamidronate-induced in-
jury, leading to a variety of glomerular lesions. A simi-
lar pattern of injury has been reported in heroin addicts.
Grishman, Churg, and Porush [21] performed renal
biopsy in 23 heroin addicts, 14 had focal segmental
glomerulosclerosis, four had minimal change disease, and
two had focal global sclerosis [21]. The authors con-
cluded that these conditions represent different phases
of the same disease process, although different reac-
tions to heroin or its various vehicles or contaminants
could not be excluded [21]. This study supports the no-
tion that a toxin may cause variable glomerular injury
within the same spectrum. Loss of synaptopodin from
podocytes has been shown in pamidronate-associated
collapsing focal segmental glomerulosclerosis [3]. In ad-
dition, pamidronate-associated acute tubular necrosis
has been recently been reported [22]. Recently, Cal
and Daley-Yates [13] and Laurinavicius, Hurwitz, and
Rennke [23] have reported acute tubular necrosis in a pa-
tient receiving high dose pamidronate for hypercalcemia.
This report is consistent with animal studies showing
pamidronate-induced tubular toxicity. Given the variety
of renal lesions associated with pamidronate, the question
remains as to why there are different renal manifesta-
tions of pamidronate in what appear to be similar clinical
settings. Some of our patients were on different dosage
regimens compared to patients previously reported, and
it is conceivable that different pamidronate regimens
may lead to different histologic changes. Alternatively,
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individual susceptibility likely plays a role in the degree
of glomerular damage. Several studies have shown that
susceptibility to renal disease may be genetic and related
to individual factors. This is especially true given that not
all patients receiving pamidronate develop renal insuffi-
ciency or proteinuria.
Various viruses have been associated with the develop-
ment of focal segmental glomerulosclerosis. This is par-
ticularly relevant in immunocompromised patients with
malignancy and chemotherapy that are usually suscep-
tible to infections. The best link is between HIV and
collapsing focal segmental glomerulosclerosis [23]. How-
ever, other viruses have been implicated to cause focal
segmental glomerulosclerosis, including hepatitis B [24]
and C [25], and more recently, parvovirus B-19 [26, 27].
The prevalence of parvovirus B-19 DNA was found to
be greater among patients with idiopathic and collaps-
ing focal segmental glomerulosclerosis compared to pa-
tients with other diagnoses, possibly representing latent
DNA from previous infection [26]. Our patients did not
have any evidence of HIV or other viral infections. How-
ever, our cohort is more consistent with pamidronate-
associated renal disease given the onset associated with
the drug administration [3].
We observed two patterns of pamidronate-induced
proteinuria. Patients 1 and 2 were enrolled in a proto-
col employing a high-dose pamidronate infusion over
a short period. Two months after completing the pro-
tocol, both patients developed severe proteinuria. The
first patient had minimal change disease while the second
showed focal segmental glomerulosclerosis. The other
three patients were on regular monthly therapy with
pamidronate. All three patients received pamidronate
for >1 year before the diagnosis. All patients had no
significant proteinuria prior to therapy (Table 1). This
pattern emphasizes the importance of monitoring for pro-
teinuria during pamidronate therapy. After discontinu-
ation of pamidronate, four of our patients maintained
a stable serum creatinine. Follow-up varied between 1
and 3 years and one patient was lost to follow up. Three
patients had complete remission of proteinuria with
24-hour urine protein of 150 mg, 136 mg, and 388 mg,
respectively, at the last date of follow up. One of the pa-
tients received steroids without response, but responded
to ACE inhibitor. The other two patients with complete
remission received only ACE inhibitor. It is difficult to
conclude whether remission is due to the use of ACE
inhibitor or would have happened anyway after stop-
ping pamidronate. It is conceivable that response was due
to the combination of stopping pamidronate and adding
ACE inhibitor. One patient continued to have significant
proteinuria despite ACE inhibitor 1 year after stopping
pamidronate but serum creatinine was stable. It is diffi-
cult to determine whether remission will occur with time.
Only one patient progressed to dialysis over a short pe-
riod of 3 months despite therapy. This particular patient
had collapsing focal segmental glomerulosclerosis that
is known to have poor prognosis and rapid progression
to end-stage renal disease (ESRD). A similar poor out-
come has been reported with collapsing focal segmental
glomerulosclerosis secondary to pamidronate with four
of seven patients progressing to ESRD despite stopping
pamidronate in two of them [3]. From this limited follow-
up, it appears that overall prognosis is favorable after
stopping pamidronate and use of ACE inhibitor except
for the histologic diagnosis of collapsing FSGS. Patient 3
had a serum creatinine of 2.8 mg/dL at the time of diag-
nosis. Proteinuria has improved and serum creatinine de-
creased to 2.0 mg/dL after pamidronate was discontinued.
It is of interest that this patient had received prolonged
therapy with pamidronate (38 months) raising the possi-
bility that pamidronate can be associated with chronic re-
nal injury. Patient 5 developed collapsing focal segmental
glomerulosclerosis after 12 months of pamidronate and
rapidly progressed to ESRD.
Kidney biopsies in our five patients varied from min-
imal change disease, through focal segmental glomeru-
losclerosis to the collapsing variant of focal segmental
glomerulosclerosis (Tables 2 and 3) and the link with
pamidronate is convincing. It is important to empha-
size the necessity of renal biopsy in this clinical setting,
particularly in patients with multiple myeloma. The pos-
sibility of myeloma-associated renal disease cannot be
excluded clinically and therapy for those conditions dif-
fers markedly from pamidronate-associated nephrotic
syndrome.
CONCLUSION
Proteinuria and podocyte injury may occur in patients
receiving any of several pamidronate regimens. Renal
biopsy may reveal any of several patterns, including min-
imal change disease, focal segmental glomerulosclerosis,
and the collapsing variant of focal segmental glomeru-
losclerosis. Discontinuation of pamidronate is critical. We
used an ACE inhibitor in each of our patients with fa-
vorable outcome in all but the patient with collapsing fo-
cal segmental glomerulosclerosis. Frequent monitoring of
urinary protein and renal function in patients receiving
pamidronate may assist in earlier detection of renal injury
and possible prevention of progressive renal failure.
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